+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07452458

Comparison of Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy with Temozolomide for Newly Diagnosed MGMT-Unmethylated Glioblastoma

Led by NRG Oncology · Updated on 2026-09-10

398

Participants Needed

54

Research Sites

286 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying newly diagnosed patients with IDH wildtype, MGMT-unmethylated glioblastoma to compare two types of radiation therapy combined with temozolomide chemotherapy. This phase III trial focuses on whether temporally-modulated pulsed radiation therapy TMPRT alongside temozolomide can better preserve memory and thinking functions and improve survival compared to standard radiation therapy with temozolomide. The study also addresses the challenges of treating MGMT-unmethylated tumors, which often respond less to chemotherapy alone. Participants are randomly assigned to one of two groups. The first group receives standard radiation therapy daily over 12-15 minutes for 3 or 6 weeks, along with daily oral temozolomide for 21 or 42 days, followed by additional temozolomide cycles every 28 days for six cycles. The second group receives TMPRT delivered in 10-13 pulses with 3-minute breaks over 30-40 minutes each session, also 5 days a week for 3 or 6 weeks, combined with the same temozolomide schedule as the first group. After radiation, both groups continue temozolomide in cycles. Throughout the trial, participants undergo CT or MRI scans and may provide optional blood samples. During the study, participants complete neurocognitive testing to track memory and thinking abilities, quality of life questionnaires, and assessments of frailty. Researchers monitor overall survival, progression-free survival, and adverse events up to 9 months after radiation therapy. Follow-up visits occur at months 1, 3, 5, 7, 9, and 12, then annually for 4 years. Blood samples are collected for future research, and imaging is used to evaluate brain changes. The trial lasts several years, with careful monitoring to evaluate the impact of the different radiation therapies combined with temozolomide.

CONDITIONS

Brief Title

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here